Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Wally R Smith, MD, Jane S. Hankins, MD MS, Miguel R Abboud, MD, Ze Cong, PhD, Jonathan Sorof, MD, Sarah Gray, PhD, Carolyn Hoppe, MD, Paul Telfer, DM, FRCP

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137121

Published: 2020

Journal Articles

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

Ahmar Urooj Zaidi, MD, Thokozeni Lipato, MD, Ofelia A. Alvarez, MD, Alexander Lonshteyn, PhD, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD, Nirmish Shah, MD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-140525

Published: 2020

Journal Articles

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

William B Ershler, MD, Laura M De Castro, MD MHSc, Zahra Pakbaz, MD, Aaron Moynahan, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-140572

Published: 2020

Journal Articles

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Xue Song, Andrew D. Campbell, MD, Ze Cong, PhD, Irene Agodoa, MD, Diane Martinez, DrPH, MPH, Carolyn R. Lew, PhD, Danae Black, Helen Varker, Chris Chan, Sophie M. Lanzkron, MD

Blood (2019) 134 (Supplement_1): 3388.

https://doi.org/10.1182/blood-2019-127173

Published: 2019

Journal Articles

Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry

Elizabeth Williams, BA, Elizabeth Brown, Deepa Manwani, MD, Payal Desai, MD, Joshua J. Field, MD, Lynne D. Neumayr, Susan Padrino, MD, E. Leila Jerome Clay, MD MCTS, FAAP, Ze Cong, PhD, Irene Agodoa, MD, Carolyn Hoppe, MD, Sophie M. Lanzkron, MD, Jane A. Little, MD

Blood (2019) 134 (Supplement_1): 2284.

https://doi.org/10.1182/blood-2019-124933

Published: 2019

Journal Articles

Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysies from the SCCRIP Cohort Study

Jeremie H. Estepp, MD, Ze Cong, PhD, Irene Agodoa, MD, Guolian Kang, PhD, Juan Ding, PhD, M. Beth McCarville, MD, Jane S. Hankins, MD MS, Winfred Wang, MD

Blood (2019) 134 (Supplement_1): 1002.

https://doi.org/10.1182/blood-2019-131177

Published: 2019

Journal Articles

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Anthony S. Stein, MD, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Max S. Topp, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Yan Li, Andre Schuh

Blood (2018) 132 (Supplement 1): 3967.

https://doi.org/10.1182/blood-2018-99-115160

Published: 2018

Journal Articles

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

Max S. Topp, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Anthony S. Stein, MD, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Andre Schuh

Blood (2018) 132 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2018-99-115123

Published: 2018

Journal Articles

A Systematic Literature Review (SLR) of Clinical Outcomes after Stem Cell Transplantation (SCT) in Adult Acute Lymphoblastic Leukemia (ALL) Patients with or without Minimal Residual Disease (MRD)

Monica Turner, Shweta Shah, Amber Martin, Ze Cong, PhD MS, Anthony S. Stein, MD

Blood (2018) 132 (Supplement 1): 5292.

https://doi.org/10.1182/blood-2018-99-112981

Published: 2018

Journal Articles

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

David Marks, Wendy Gidman, PhD MSc, BPharm, Heather M Wieffer, PhD, Lirong Zhang, MSc, Ze Cong, PhD MS, Shweta Shah

Blood (2018) 132 (Supplement 1): 5865.

https://doi.org/10.1182/blood-2018-99-118029

Published: 2018

Journal Articles

Healthcare Resource Utilization in Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia in First Hematologic Complete Remission with and without Minimal Residual Disease

Darya Rose, Shweta Shah, Nicholas Despiegel, Shruti Tibrewala, MBA, MPH, Anita Chawla, Ze Cong, PhD MS

Blood (2018) 132 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2018-99-111360

Published: 2018

Journal Articles

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Thomas Delea, MBA, MSIA, Nicholas Despiegel, Diana Boyko, Jordan Amdahl, Ze Cong, PhD MS, Jerald Radich, MD

Blood (2018) 132 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2018-99-115230

Published: 2018

Journal Articles

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Max S. Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Anthony Stein, Janet Franklin, Qui Tran, Ze Cong, Andre C. Schuh

Blood (2018) 131 (26): 2906–2914.

https://doi.org/10.1182/blood-2017-09-804658

Published: 2018

Includes: Supplemental data

Journal Articles

Economic Burden of Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Acute Lymphoblastic Leukemia (ALL) in the US

Xinke Zhang, PhD, Xue Song, PhD, Lorena Lopez-Gonzalez, PhD, Krutika Jariwala-Parikh, PhD, Ze Cong, PhD

Blood (2017) 130 (Supplement 1): 3376.

https://doi.org/10.1182/blood.V130.Suppl_1.3376.3376

Published: 2017

Journal Articles

Economic Burden of Veno-Occlusive Disease (VOD) in Patients with Acute Lymphoblastic Leukemia (ALL) in the US

Xinke Zhang, PhD, Xue Song, PhD, Lorena Lopez-Gonzalez, PhD, Krutika Jariwala-Parikh, PhD, Vadim Romanov, MD Mphil, FFPM, Ze Cong, PhD

Blood (2017) 130 (Supplement 1): 5611.

https://doi.org/10.1182/blood.V130.Suppl_1.5611.5611

Published: 2017

Journal Articles

Economic Burden Associated with Adverse Events of Special Interest (AESI) in Patients with Relapsed Acute Lymphoblastic Leukemia (ALL) in the US

Xinke Zhang, PhD, Xue Song, PhD, Lorena Lopez-Gonzalez, PhD, Krutika Jariwala-Parikh, PhD, Vadim Romanov, MD Mphil, FFPM, Ze Cong, PhD

Blood (2017) 130 (Supplement 1): 4683.

https://doi.org/10.1182/blood.V130.Suppl_1.4683.4683

Published: 2017

Journal Articles

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Max S. Topp, MD, Zachary F. Zimmerman, MD PhD, Paul Cannell, MD, Herve Dombret, MD, Anthony S. Stein, MD, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong, PhD, Andre Schuh, MD FRCPC

Blood (2017) 130 (Supplement 1): 2571.

https://doi.org/10.1182/blood.V130.Suppl_1.2571.2571

Published: 2017

Journal Articles

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Max S Topp, MD, Zachary Zimmerman, MD PhD, Paul Cannell, MD, Hervé Dombret, MD PhD, Johan Maertens, MD PhD, Andre C. Schuh, MD FRCPC, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong

Blood (2016) 128 (22): 222.

https://doi.org/10.1182/blood.V128.22.222.222

Published: 2016

Journal Articles

Healthcare Costs Associated with Adult Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in the US

Nicole Princic, Xue Song, PhD, Vincent Lin, Ze Cong

Blood (2016) 128 (22): 5940.

https://doi.org/10.1182/blood.V128.22.5940.5940

Published: 2016

Journal Articles

Patterns of Medication Use in Patients with Relapsed and/or Refractory Multiple Myeloma

May Hagiwara, PhD, Aaron Moynahan, MA, Ze Cong, Yaozhu J. Chen, MPA, Emilie Duchesneau, BA, Dana Hurley, PharmD, MS, Thomas E. Delea, MSIA

Blood (2015) 126 (23): 4497.

https://doi.org/10.1182/blood.V126.23.4497.4497

Published: 2015

NARROW

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry

Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysies from the SCCRIP Cohort Study

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

A Systematic Literature Review (SLR) of Clinical Outcomes after Stem Cell Transplantation (SCT) in Adult Acute Lymphoblastic Leukemia (ALL) Patients with or without Minimal Residual Disease (MRD)

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

Healthcare Resource Utilization in Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia in First Hematologic Complete Remission with and without Minimal Residual Disease

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Economic Burden of Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Acute Lymphoblastic Leukemia (ALL) in the US

Economic Burden of Veno-Occlusive Disease (VOD) in Patients with Acute Lymphoblastic Leukemia (ALL) in the US

Economic Burden Associated with Adverse Events of Special Interest (AESI) in Patients with Relapsed Acute Lymphoblastic Leukemia (ALL) in the US

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Healthcare Costs Associated with Adult Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in the US

Patterns of Medication Use in Patients with Relapsed and/or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only